Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk - Scorecard - MDSpire

Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk

  • By

  • Jun Luo

  • Yinzhong Dai

  • Chenguang Wu

  • Chengying Lan

  • Junwei Shi

  • Jinfeng Qi

  • Shimei Hua

  • Yan An

  • Lifan Wang

  • Ping Li

  • Peng Liu

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Evaluating the Effectiveness of Lipid-Lowering Treatments on Cardio-Renal-Metabolic Outcomes in Diabetic Kidney Disease: A Bayesian Network Meta-Analysis of Residual CRM Risk

At a Glance

CategoryDetail
Condition
Key MechanismsDyslipidemia accelerates renal decline and heart failure risk, necessitating lipid-lowering therapy.
Target Population
Care Setting

Key Highlights

  • Cerivastatin most effectively reduced Total Cholesterol.
  • Simvastatin most effectively lowered Low-Density Lipoprotein Cholesterol.
  • Atorvastatin and Fenofibrate robustly reduced cardiovascular event rates.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of DKD should consider the presence of dyslipidemia.

Management

  • Statins are recommended for cardiovascular risk management in DKD.

Monitoring & Follow-up

  • Monitor lipid levels and cardiovascular events in DKD patients.

Risks

  • Patients with DKD have elevated cardiovascular event rates and mortality.

Patient & Prescribing Data

Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease.

Atorvastatin and Fenofibrate are effective in reducing cardiovascular risks despite variable renal effects.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk

    • by Jun Luo, Yinzhong Dai, Chenguang Wu, Chengying Lan, Junwei Shi, Jinfeng Qi, Shimei Hua, Yan An, Lifan Wang, Ping Li, Peng Liu

    • May 29, 2026

    Related Content

    Editorial: Addressing the Challenges of Diabetes Complications and Exploring Innovative Approaches